Literature DB >> 24423981

Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Harrison G Pope1, Ruth I Wood, Alan Rogol, Fred Nyberg, Larry Bowers, Shalender Bhasin.   

Abstract

Despite the high prevalence of performance-enhancing drug (PED) use, media attention has focused almost entirely on PED use by elite athletes to illicitly gain a competitive advantage in sports, and not on the health risks of PEDs. There is a widespread misperception that PED use is safe or that adverse effects are manageable. In reality, the vast majority of PED users are not athletes but rather nonathlete weightlifters, and the adverse health effects of PED use are greatly underappreciated. This scientific statement synthesizes available information on the medical consequences of PED use, identifies gaps in knowledge, and aims to focus the attention of the medical community and policymakers on PED use as an important public health problem. PED users frequently consume highly supraphysiologic doses of PEDs, combine them with other PEDs and/or other classical drugs of abuse, and display additional associated risk factors. PED use has been linked to an increased risk of death and a wide variety of cardiovascular, psychiatric, metabolic, endocrine, neurologic, infectious, hepatic, renal, and musculoskeletal disorders. Because randomized trials cannot ethically duplicate the large doses of PEDs and the many factors associated with PED use, we need observational studies to collect valid outcome data on the health risks associated with PEDs. In addition, we need studies regarding the prevalence of PED use, the mechanisms by which PEDs exert their adverse health effects, and the interactive effects of PEDs with sports injuries and other high-risk behaviors. We also need randomized trials to assess therapeutic interventions for treating the adverse effects of PEDs, such as the anabolic-androgen steroid withdrawal syndrome. Finally, we need to raise public awareness of the serious health consequences of PEDs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24423981      PMCID: PMC4026349          DOI: 10.1210/er.2013-1058

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  386 in total

1.  A brief history of testosterone.

Authors:  E R Freeman; D A Bloom; E J McGuire
Journal:  J Urol       Date:  2001-02       Impact factor: 7.450

Review 2.  The relationship between anabolic androgenic steroids and muscle dysmorphia: a review.

Authors:  Lebur Rohman
Journal:  Eat Disord       Date:  2009 May-Jun       Impact factor: 3.222

3.  Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly.

Authors:  P J Jenkins; V Frajese; A M Jones; C Camacho-Hubner; D G Lowe; P D Fairclough; S L Chew; A B Grossman; J P Monson; G M Besser
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

4.  Anabolic steroids and violent crime--an epidemiological study at a jail in Stockholm, Sweden.

Authors:  G Isacsson; M Garle; E B Ljung; U Asgård; U Bergman
Journal:  Compr Psychiatry       Date:  1998 Jul-Aug       Impact factor: 3.735

5.  Hepatic angiosarcoma associated with androgenic-anabolic steroids.

Authors:  T K Daneshmend; J W Bradfield
Journal:  Lancet       Date:  1979-12-08       Impact factor: 79.321

6.  Contrasting effects of testosterone and stanozolol on serum lipoprotein levels.

Authors:  P D Thompson; E M Cullinane; S P Sady; C Chenevert; A L Saritelli; M A Sady; P N Herbert
Journal:  JAMA       Date:  1989-02-24       Impact factor: 56.272

Review 7.  Heart disease induced by AAS abuse, using experimental mice/rats models and the role of exercise-induced cardiotoxicity.

Authors:  I Riezzo; D De Carlo; M Neri; A Nieddu; E Turillazzi; V Fineschi
Journal:  Mini Rev Med Chem       Date:  2011-05       Impact factor: 3.862

8.  Anorexia nervosa and "reverse anorexia" among 108 male bodybuilders.

Authors:  H G Pope; D L Katz; J I Hudson
Journal:  Compr Psychiatry       Date:  1993 Nov-Dec       Impact factor: 3.735

Review 9.  Anabolic androgenic steroids and forebrain GABAergic transmission.

Authors:  L P Henderson; C A A Penatti; B L Jones; P Yang; A S Clark
Journal:  Neuroscience       Date:  2005-11-28       Impact factor: 3.590

Review 10.  Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions.

Authors:  Isela Velazquez; Blanche P Alter
Journal:  Am J Hematol       Date:  2004-11       Impact factor: 10.047

View more
  107 in total

Review 1.  Doping with anabolic androgenic steroids (AAS): Adverse effects on non-reproductive organs and functions.

Authors:  Eberhard Nieschlag; Elena Vorona
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

Review 2.  Mad men, women and steroid cocktails: a review of the impact of sex and other factors on anabolic androgenic steroids effects on affective behaviors.

Authors:  Marie M Onakomaiya; Leslie P Henderson
Journal:  Psychopharmacology (Berl)       Date:  2016-01-12       Impact factor: 4.530

3.  Anabolic-androgenic steroids and decision making: Probability and effort discounting in male rats.

Authors:  Kathryn G Wallin; Jasmin M Alves; Ruth I Wood
Journal:  Psychoneuroendocrinology       Date:  2015-04-04       Impact factor: 4.905

4.  Predictors of muscularity-oriented disordered eating behaviors in U.S. young adults: A prospective cohort study.

Authors:  Jason M Nagata; Stuart B Murray; Kirsten Bibbins-Domingo; Andrea K Garber; Deborah Mitchison; Scott Griffiths
Journal:  Int J Eat Disord       Date:  2019-06-20       Impact factor: 4.861

Review 5.  Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?

Authors:  Marc J Kaufman; Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Neurosci Biobehav Rev       Date:  2019-02-25       Impact factor: 8.989

6.  Glomerular Filtration Rate and Supraphysiologic-Dose Anabolic-Androgenic Steroid Use: A Cross-sectional Cohort Study.

Authors:  James I Hudson; Gen Kanayama; Harrison G Pope; Samantha Muse; Marc J Kaufman; Aaron Baggish; Sushrut S Waikar
Journal:  Am J Kidney Dis       Date:  2020-04-30       Impact factor: 8.860

7.  Anabolic-androgenic steroids impair set-shifting and reversal learning in male rats.

Authors:  Kathryn G Wallin; Ruth I Wood
Journal:  Eur Neuropsychopharmacol       Date:  2015-01-20       Impact factor: 4.600

8.  Homicidality and Psychosis Caused by an Over-the-Counter Performance-Enhancing Supplement Containing Dendrobium Extract and L-Dopa.

Authors:  Alexandra Flynn; Jana Lincoln; Michael Burke
Journal:  P T       Date:  2016-06

9.  Intracerebroventricular Oxytocin Self-Administration in Female Rats.

Authors:  M E Donhoffner; S P Goings; K Atabaki; R I Wood
Journal:  J Neuroendocrinol       Date:  2016-10       Impact factor: 3.627

10.  Severe rhinovirus pneumonia in a young woman taking performance-enhancing drugs.

Authors:  Kristina Nadine Mayer; Daniel Wyder; Danijela Spasic; Thomas Herren
Journal:  BMJ Case Rep       Date:  2016-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.